Compare AMPX & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPX | TARS |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | 109 | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.7B |
| IPO Year | N/A | 2020 |
| Metric | AMPX | TARS |
|---|---|---|
| Price | $22.29 | $64.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $20.17 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 7.2M | 408.4K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $76.15 | $56.56 |
| Revenue Next Year | $59.65 | $29.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $1.97 | $38.51 |
| 52 Week High | $20.19 | $85.25 |
| Indicator | AMPX | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 69.16 | 36.99 |
| Support Level | $10.00 | $61.24 |
| Resistance Level | N/A | $67.70 |
| Average True Range (ATR) | 1.65 | 2.84 |
| MACD | 0.31 | -0.59 |
| Stochastic Oscillator | 93.09 | 11.63 |
Amprius Technologies Inc is engaged in the production of silicon anodes for high-energy-density lithium-ion batteries. The company develops, manufactures and markets lithium-ion batteries for mobility applications, including the aviation, electric vehicle (EV) and light electric vehicle (LEV) industries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites. Its silicon anodes are a direct drop-in replacement of the graphite anode in traditional lithium-ion batteries, and its manufacturing processes leverage the manufacturing processes for conventional lithium-ion batteries and the related supply chain.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.